Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Schliemann

Showing results (351-360 of 427) with videos related to

Pageof 43
Sort By:
Plos One|October 28, 2017
Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancerLars Henning Schmidt, Birthe Heitkötter, Arik B Schulze, et al.
Cancer Gene Therapy|June 30, 2023
CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering processBianca Altvater, Sareetha Kailayangiri, Christian Spurny, et al.
Oncotarget|October 15, 2016
Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarctionJanine Stucke-Ring, Julian Ronnacker, Caroline Brand, et al.
Journal of the American Academy of Dermatology|March 13, 2025
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trialsMelinda Gooderham, Sonja Molin, Robert Bissonnette, et al.
Annals of Hematology|November 18, 2022
A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapyAndrew F Berdel, Raphael Koch, Joachim Gerss, et al.
British Journal of Haematology|February 23, 2018
High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemiaNina K Steckel, Christoph Groth, Jan-Henrik Mikesch, et al.
Annals of Hematology|March 24, 2019
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, et al.
Nature Genetics|September 22, 2025
Rapid epigenomic classification of acute leukemiaTil L Steinicke, Salvatore Benfatto, Maria R Capilla-Guerra, et al.
Transplantation and Cellular Therapy|December 17, 2025
Pretransplant HMA and Venetoclax in AML patients - a Real-World Analysis from the Cooperative Transplant Study GroupChristina Rautenberg, Matthias Stelljes, Gesine Bug, et al.
Blood Neoplasia|January 9, 2026
Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022Andrew F Berdel, Julian Ronnacker, Daniela V Wenge, et al.
Pageof 43

Showing results (351-360 of 427) with videos related to

Sort By:
Pageof 43
Plos One|October 28, 2017
Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancerLars Henning Schmidt, Birthe Heitkötter, Arik B Schulze, et al.
Cancer Gene Therapy|June 30, 2023
CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering processBianca Altvater, Sareetha Kailayangiri, Christian Spurny, et al.
Oncotarget|October 15, 2016
Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarctionJanine Stucke-Ring, Julian Ronnacker, Caroline Brand, et al.
Journal of the American Academy of Dermatology|March 13, 2025
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trialsMelinda Gooderham, Sonja Molin, Robert Bissonnette, et al.
Annals of Hematology|November 18, 2022
A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapyAndrew F Berdel, Raphael Koch, Joachim Gerss, et al.
British Journal of Haematology|February 23, 2018
High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemiaNina K Steckel, Christoph Groth, Jan-Henrik Mikesch, et al.
Annals of Hematology|March 24, 2019
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, et al.
Nature Genetics|September 22, 2025
Rapid epigenomic classification of acute leukemiaTil L Steinicke, Salvatore Benfatto, Maria R Capilla-Guerra, et al.
Transplantation and Cellular Therapy|December 17, 2025
Pretransplant HMA and Venetoclax in AML patients - a Real-World Analysis from the Cooperative Transplant Study GroupChristina Rautenberg, Matthias Stelljes, Gesine Bug, et al.
Blood Neoplasia|January 9, 2026
Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022Andrew F Berdel, Julian Ronnacker, Daniela V Wenge, et al.
Pageof 43